1. Home
  2. SNGX vs DSS Comparison

SNGX vs DSS Comparison

Compare SNGX & DSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Soligenix Inc.

SNGX

Soligenix Inc.

SELL

Current Price

$0.36

Market Cap

8.2M

Sector

Health Care

ML Signal

SELL

Logo DSS Inc.

DSS

DSS Inc.

BUY

Current Price

$0.63

Market Cap

7.0M

ML Signal

BUY

Company Overview

Basic Information
Metric
SNGX
DSS
Founded
1987
1984
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Containers/Packaging
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
8.2M
7.0M
IPO Year
2006
2020

Fundamental Metrics

Financial Performance
Metric
SNGX
DSS
Price
$0.36
$0.63
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 212.3K
88.5K
Earning Date
11-06-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 57.03
42.45
EPS
★ N/A
N/A
Revenue
$119,371.00
★ $2,085,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$43.35
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.28
$0.36
52 Week High
$1.97
$1.86

Technical Indicators

Market Signals
Indicator
SNGX
DSS
Relative Strength Index (RSI) 40.49 43.14
Support Level $0.35 $0.49
Resistance Level $0.41 $1.05
Average True Range (ATR) 0.01 0.05
MACD -0.00 -0.02
Stochastic Oscillator 6.98 11.76

Price Performance

Historical Comparison
SNGX
DSS

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).

About DSS DSS Inc.

DSS Inc is operating a business focused on four operating segments: Product Packaging, Biotechnology, Commercial Lending, and Securities and Investment Management. Currently operates five distinct business lines that operate around the globe with primary operations in North America and Asia. Product packaging manufactures and sells sophisticated custom folding cartons, mailers, photo sleeves, and complex three-dimensional direct mail solutions. The biotechnology division targets unmet, urgent medical needs and expands the borders of medical and pharmaceutical science. Commercial Lending represents its banking and financing business line. Alternative Trading develops and/or acquires assets and investments in the Securities and Investment Management.

Share on Social Networks: